The United States and United Kingdom Announce Duty-Free Deal on Medicines.

The United Kingdom and the United States have announced a important bilateral deal that will preserve zero levies on UK medicine products entering the US market.

The Terms of the Deal

Under the terms of the agreement, the UK has agreed to raise spending on drugs through the NHS. This move ensures that import taxes on these vital goods will be held at nothing for a duration of the next three years.

This agreement comes after previous threats to hike tariffs on branded pharmaceutical imports, with figures floated as high as double the cost.

"This agreement with the United Kingdom reinforces the global environment for innovative medicines and introduces long-overdue balance to U.S.–U.K. drug exports," an announcement noted.

Commercial Significance

Pharmaceuticals represent one of the Britain's largest export categories to the US, which is clearly the largest buyer for major companies like GSK and AstraZeneca.

Trade data indicate that in the 12 months prior to September, the UK shipped drugs totaling over eleven billion pounds to the US. This figure accounted for nearly one-fifth of British export trade in that span.

"This deal safeguards work, increases investment and facilitates the UK to become a global hub for biotech and pharma," a government official remarked.

Specific NHS Changes

The deal involves several specific commitments from the UK:

• Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new medicines to be prohibitively costly by a quarter.
• Boosted Medicine Funding: There is a aim to increase overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
• Rebate Cap: The amount pharmaceutical firms must return to the NHS to prevent overspending will be limited at fifteen percent. Last year, refunds topped twenty percent.

Recent Tensions

The pact takes place against a protracted row between the pharmaceutical industry and the ministers over spending levels and approval rates.

This friction were intensified by assertions that American patients were paying a premium for the same drugs than patients in the UK and Europe.

In recent months, several major drug company projects in the UK have been delayed or abandoned, while major funding commitments have been pledged toward US facilities.

A senior figure stated that the NHS must spend more on medicines, noting that its expenditure on drugs had declined as a proportion of its overall budget over the previous ten-year period.